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Comparison of MRI and colonoscopy in
determining tumor height in rectal cancer
Lotte Jacobs1, David B Meek2, Joost van Heukelom1, Thomas L Bollen2,
Peter D Siersema3,4, Anke B Smits5, Ellen Tromp6, Maartje Los7,
Bas LAM Weusten1,3 and Niels van Lelyveld1
Abstract
Background and aim: Endoscopy and magnetic resonance imaging (MRI) are used routinely in the diagnostic and pre-
operative work-up of rectal cancer. We aimed to compare colonoscopy and MRI in determining rectal tumor height.
Methods: Between 2002 and 2012, all patients with rectal cancer with available MRIs and endoscopy reports were included.
All MRIs were reassessed for tumor height by two abdominal radiologists. To obtain insight in techniques used for endo-
scopic determination of tumor height, a survey among regional endoscopists was conducted.
Results: A total of 211 patients with rectal cancer were included. Tumor height was significantly lower when assessed by
MRI than by endoscopy with a mean difference of 2.5 cm (95% CI: 2.1–2.8). Although the agreement between tumor height
as measured by MRI and endoscopy was good (intraclass correlation coefficient (ICC) 0.7 (95% CI: 0.7–0.8)), the 95% limits of
agreement varied from –3.0 cm to 8.0 cm. In 45 patients (21.3%), tumors were regarded as low by MRI and middle–high by
endoscopy. MRI inter- and intraobserver agreements were excellent with an ICC of 0.8 (95% CI: 0.7–0.9) and 0.9 (95% CI:
0.9–1.0), respectively. The survey showed no consensus among endoscopists as to how to technically measure tumor height.
Conclusion: This study showed large variability in rectal tumor height as measured by colonoscopy and MRI. Since MRI
measurements showed excellent inter- and intraobserver agreement, we suggest using tumor height measurement by MRI
for diagnostic purposes and treatment allocation.
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Introduction
Endoscopy is the preferred diagnostic method for
evaluation of rectal cancer. In the preoperative work-
up of patients with rectal cancer, pelvic magnetic res-
onance imaging (MRI) is performed routinely for
locoregional tumor staging.1,2 Clinicians often use
either one or both modalities to determine rectal
tumor height.
Rectal tumor height can be deﬁned as the distance
between the distal end of the tumor and one of the
following landmarks: the anorectal junction (ARJ),
dentate line, or anal verge. The ARJ, which is the
upper margin of the anal canal, is the junction between
the rectal columnar epithelium and the squamous epi-
thelium of the anal canal. Just above the ARJ, the
rectum will be increasingly surrounded by perirectal
fat of the mesorectum. The mesorectum is important
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for surgeons to ensure a free resection margin to the
mesorectal fascia.
Endoscopic landmarks include the dentate line and
anal verge. The dentate line lies just beneath the ARJ
and is a scalloped demarcation formed by the anal
valves, the beginning of the columns of Morgagni.
The anal verge is the junction of hair-bearing skin of
the buttocks to non-hair-bearing skin of the anal canal
and both are covered with squamous epithelium.
There is radiological consensus as to how to measure
rectal tumor height by MRI using the ARJ as a land-
mark, which is used preferably by surgeons.3 However,
according to international clinical guidelines, rectal
tumor height should be measured by rigid sigmoidos-
copy and is deﬁned as the distance from the anal
verge.1,2 Rigid sigmoidoscopy is not used consistently
in clinical practice, and is increasingly replaced by ﬂex-
ible endoscopy. Furthermore, for ﬂexible endoscopy a
standardized method for rectal tumor height measure-
ment is lacking. Hence, measurements by these various
techniques may diﬀer, potentially leading to alternative
treatment strategies. It is well established that neoadju-
vant therapy, surgical treatment, and patient outcome
diﬀer between lower and higher rectal tumors, with
lower rectal tumors being associated with a higher
local recurrence rate and worse survival.1,2,4–8
In the literature, no consensus exists on the preferred
method to determine rectal tumor height. In addition,
data on the interchangeability of ﬂexible endoscopy
and MRI in determining rectal tumor height are lack-
ing. Major trials on rectal cancer did not use a uniform
deﬁnition of rectal tumor height, particularly regarding
the distal end of the rectal tumor.4,9–11 Universal adop-
tion of a standardized technique for assessment of
rectal tumor height would likely facilitate comparison
of study results of rectal cancer treatment.
Given the varying landmarks for deﬁning rectal
tumor height and their repercussions on treatment
management and outcome, the primary aim of this
study was to compare colonoscopy and MRI for deter-
mining rectal tumor height. Since there is no consensus
on what method should be used for determining the
rectal tumor height, we aimed to select the best
method to improve standardized reporting of rectal
tumors.
Patients and methods
Patient selection and database
Data of all patients with pathologically conﬁrmed
rectal carcinoma at a large urban teaching hospital
between January 2002 and January 2012 were extracted
from the Netherlands Cancer Registry. All patients
with available MRI data and complete endoscopy
reports (with tumor height) were included. This study
was approved by the medical ethics research committee
under registration number W13.018.
Endoscopy
Endoscopy reports of all patients were reviewed.
Patients were included only if an exact rectal tumor
height was mentioned in the endoscopy report. Since
endoscopy was always performed before MRI, endo-
scopic tumor height data were independent from MRI
results. To obtain insight in the techniques used for the
endoscopic determination of rectal tumor height, a
survey among regional endoscopists was conducted.
MRI protocol and measurements
Since 2006, MRI was added in our center as standard
procedure for staging rectal cancer. Images of the lower
pelvis were obtained using a 1.5T MRI scanner (Philips
Medical Systems International BV, Best, The
Netherlands). Standard MRI protocol consisted of
T2-weighted sequences in three planes perpendicular
to the rectal wall at the level of the rectal mass, an
axial T1-weighted sequence, and diﬀusion-weighted
imaging. Two abdominal radiologists reviewed in con-
sensus all MRI studies for assessment of rectal tumor
height. Both radiologists were blinded to endoscopy
results. The sagittal T2-weighted sequence was used to
determine the shortest distance in centimeters between
the ARJ to the lower pole of the rectal tumor. The ARJ
was identiﬁed as the transition from the puborectal
complex (low signal on T2-weighted sequence) and
the rectal wall (intermediate signal on T2-weighted
sequence).3,12
To assess the reproducibility of MRI-deﬁned tumor
height, we performed an interobserver agreement ana-
lysis between reassessed rectal tumor heights and those
mentioned in the initial reports. Also, intraobserver
agreement analysis was performed one year after the
MRI measurements by both radiologists in consensus
in a randomly chosen group of 20 MRIs, blinded to the
initial rectal tumor height results and endoscopy
results.
Statistical analysis
Data were analyzed using SPSS version 22 for
Windows (SPSS Inc, Chicago, IL, USA). Means with
standard deviation (SD) and ranges were calculated.
Diﬀerences between MRI and endoscopy were tested
using a paired T-test. Agreement between the measure-
ments was tested using intraclass correlation coeﬃcient
(ICC) (two-way mixed, consistency, single measures)
and Bland-Altman analysis.13 Inter- and intraobserver
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variability was assessed using ICC.14 ICC values 0.75
were considered as excellent agreement, 0.4–0.75 as fair
to good agreement, and <0.4 as poor agreement.14
Subsequently, data were stratiﬁed into three groups,
with rectal tumor location classiﬁed as low from 0 to
5 cm, as middle from 5.1 cm to 10 cm, and as high from
10.1 cm to 15 cm, with respect to the ARJ. Lesions with
rectal tumor height more than 15 cm from the ARJ
were deﬁned as sigmoid tumors. Diﬀerences between
the MRI and endoscopy groups were tested using a
McNemar test. A p value of <0.05 was considered stat-
istically signiﬁcant.
Results
Patient characteristics
During the study period, a total of 513 patients with
pathologically conﬁrmed rectal carcinoma were identi-
ﬁed, of whom 265 patients (51.7%) underwent MRI as
part of the preoperative work-up. Of these, 54 patients
were excluded because of incomplete (n¼ 9) or no
(n¼ 45) endoscopy report available for review. The ﬁnal
study cohort consisted of 211 patients (41.1%), of whom
60.2% were male. Mean age was 65 years (range, 36–91).
Clinical stage of included patients was stage I, 11.8%;
stage II, 8.1%; stage III, 57.8%, and stage IV, 22.3%.
A ﬂowchart of patient selection is shown in Figure 1.
Endoscopy results
Mean rectal tumor height of 211 patients measured by
endoscopy was 6.7 cm (SD 4.4 cm, range 0–15 cm).
Survey results
A questionnaire was sent to 51 regional endoscopists
with a response rate of 82.4%. Only half of the respon-
ders determined the distance with digital rectal examin-
ation if possible. The majority used ﬂexible endoscopy as
opposed to a rigid endoscopy for measuring rectal tumor
height. About two-thirds of the endoscopists determined
the distance in centimeters externally on the scope. Five
endoscopists applied an arbitrary correction factor to
compensate for the length of the anal canal. An overview
of the survey results is depicted in Table 1.
MRI results
The mean rectal tumor height of 211 patients measured
by MRI after reassessment was 4.2 cm (SD 3.3 cm,
range 0–15 cm). All tumors were detected by both radi-
ologists. In only 80 of 211 initial reports (37.9%) was
an exact rectal tumor height mentioned. The remainder
of 131 reports did not mention tumor height and the
majority of these were dated before 2010 (74%). The
mean rectal tumor height of these 80 patients was
4.8 cm (SD 4.0 cm, range 0–15 cm). This was slightly
higher than the reassessed mean rectal tumor height of
these 80 patients (3.9 cm (SD 3.6 cm, range 0–15 cm))
with a mean diﬀerence of 0.9 cm (95% conﬁdence inter-
val (CI): 0.4–1.4, p< 0.001). The distribution of tumor
stages and locations was: T1 n¼ 16 (22%), T2 n¼ 16
(22%), T3 n¼ 22 (30%) and T4 n¼ 19 (26%), respect-
ively, ‘‘low’’ n¼ 51 (64%), ‘‘middle’’ n¼ 24 (30%) and
‘‘high’’ n¼ 5 (6%). The interobserver agreement was
excellent (ICC 0.8 (95% CI: 0.7–0.9), Figure 2(a)).
Patients with histologically confirmed rectal
adenocarcinoma stage I– IV
n=513 (100%)
MRI available
n=265 (51.7%)
No MRI
n=248 (48.3%)
No endoscopy report
n=45 (8.8%)
Incomplete endoscopy report
n=9 (1.8%)
Both MRI and endoscopy report
n=220 (42.9%)
Patients included for analysis
n=211 (41.1%)
Figure 1. Flow diagram of patient selection.
MRI: magnetic resonance imaging.
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Review of 20 MRIs one year later by both radiolo-
gists resulted in a mean rectal tumor height of 5.1 cm
(SD 3.2 cm, range 0–15 cm). This was slightly lower
than the initial rectal tumor heights (5.8 cm (SD
3.7 cm, range 0–15 cm)) with a mean diﬀerence of
0.7 cm (95% CI: 0.2–1.3, p¼ 0.015). The distribution
of tumor stages and locations was: T1 n¼ 4 (20%),
T2 n¼ 6 (30%), T3 n¼ 7 (35%) and T4 n¼ 2 (10%),
one missing data (5%), respectively, ‘‘low’’ n¼ 8 (40%),
‘‘middle’’ n¼ 9 (45%) and ‘‘high’’ n¼ 3 (15%). The
intraobserver agreement was excellent (ICC 0.9 (95%
CI: 0.9–1.0), Figure 2(b)). There was no signiﬁcant dif-
ference in agreement between the group of 80 patients
and the group of 20 patients (p¼ 0.51).
Rectal tumor height and correlation between MRI
and endoscopy
Rectal tumor height was signiﬁcantly lower when
assessed by MRI than by endoscopy, with a mean dif-
ference of 2.5 cm (95% CI: 2.1–2.8, p< 0.001). The
agreement between rectal tumor height measured by
MRI and endoscopy was good (ICC 0.7 (95% CI:
0.7–0.8), Figure 3). However, the 95% limits of agree-
ment between endoscopy and MRI measurements
varied from –3.0 cm (95% CI: –3.7 to –2.4) to 8.0 cm
(95% CI: 7.3 to 8.6). Figure 4 shows the Bland-Altman
plot with mean diﬀerences and limits of agreement,
clearly showing large variability between endoscopy
and MRI measurements.
Tumor distribution
Rectal tumors were categorized as low (0–5.0 cm),
middle (5.1–10 cm) or high (10.1–15.0 cm). Tumors
were classiﬁed as low in 130 patients (61.6%) by MRI
and 90 patients (42.7%) by endoscopy (p< 0.05). In 45
patients (21.3%), rectal tumors were regarded as low by
MRI but as middle–high by endoscopy. Table 2 shows
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Figure 2. (a) Relation between reassessed magnetic resonance imaging (MRI) tumor heights and tumor heights mentioned in initial MRI
reports (n¼ 80). X-axis depicts reassessed MRI tumor heights (cm), Y-axis depicts tumor height mentioned in initial MRI reports (cm).
(b) Relation between MRI tumor height measurements and MRI tumor heights measured one year later by both radiologists (n¼ 20).
X-axis depicts MRI measurements (cm), Y-axis depicts MRI measurements one year later (cm).
Table 1. Survey results
Survey results
Endoscopists
(n¼ 42)
Scope type
Flexible scope 40 (95.2%)
Rigid scope 2 (4.8%)
Digital rectal examination
Yes 21 (50%)
No 21 (50%)
Scope tip placed at distal end of tumor and
distance determined externally on scope
26 (61.9%)
Applying correction factor to compensate for
anal canal length
5 (11.9%)
Retract scope to dentate line and determine
distance again
13 (31.0%)
Scope tip placed at dentate line and insert a
(biopsy) device until distal end of tumor,
retract scope including inserted (biopsy)
device and externally determine length of
device
1 (2.4%)
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Figure 4. Bland-Altman plot of difference in measurements of tumor height using endoscopy and magnetic resonance imaging.
Differences between measurements are given in centimeters. Reference interval given 95% limits of agreement (dashed lines) and their
corresponding 95% confidence interval (dotted lines).
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Figure 3. Relation between endoscopic and magnetic resonance imaging (MRI) tumor height measurements (n¼ 211).
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the tumor distribution in groups as measured by MRI
and endoscopy.
Discussion
The main ﬁnding of this study is that measurement of
rectal tumor height is signiﬁcantly lower (2.5 cm) when
assessed by MRI compared with ﬂexible endoscopy.
Although the ICC was good (0.7), the wide 95% limits
of agreement (–3.0 cm to 8.0 cm) show a large variability
between both measurements. Furthermore, the Bland-
Altman analysis showed that no standard correction
factor can be applied to account for the discrepant meas-
urements. Our study revealed that a signiﬁcant propor-
tion of rectal tumors were endoscopically classiﬁed as
middle–high but as low by MRI assessment. This may
result in considerable consequences for patient manage-
ment and surgical decision making.
The results of our survey among regional endosco-
pists conﬁrmed that no consensus exists concerning the
determination of rectal tumor height by endoscopy. We
found that endoscopists use various ways to technically
measure rectal tumor height. Obviously, these measure-
ments are subjective and not easily reproducible.
Although rigid sigmoidoscopy is recommended by
international clinical guidelines in determining rectal
tumor height, only 2% of the responders indeed use
both rigid sigmoidoscopy and ﬂexible endoscopy.
Importantly, ﬂexible and rigid proctosigmoidoscopy
for determining rectal tumor height are not inter-
changeable according to Schoellhammer et al. Their
study showed that treatment options changed signiﬁ-
cantly in 25% of rectal cancer patients. Consequently,
some patients with colon cancer in whom the tumor is
incorrectly localized in the rectum, may be overtreated
with neoadjuvant chemoradiation, while others may
have beneﬁted from neoadjuvant chemoradiation
before resection.15 Three previous retrospective studies
have compared rigid proctosigmoidoscopy with MRI-
deﬁned tumor height. These studies concluded that
measurements by both techniques indeed diﬀer signiﬁ-
cantly and are not interchangeable.16–18 Only one small
study by Paparo et al., including 66 patients, concluded
that MRI measurements of rectal tumor height corre-
lated well with rigid proctosigmoidoscopy. These
authors used the anal verge as a landmark and their
levels of agreement were –15.7 cm to 4.7 cm, clearly
showing a large variability between the measure-
ments.19 In regular clinical practice, ﬂexible endoscopes
are used that may bend and thereby add a few centi-
meters to the true distance. Furthermore, the distance
hallmarks on the endoscopes are spaced 5 cm apart,
which may lead to mistakes in measuring distances.
Finally, determining rectal tumor height by endoscopy
is subjective and not easily repeatable.
In the radiologic literature, there is consensus on the
best method to measure rectal tumor height at MRI by
using the ARJ as a referencing landmark.3 In our study,
the inter- and intraobserver agreement in determining
rectal tumor height at MRI was excellent. Moreover, in
contrast to endoscopy measurements, MRI measure-
ments are easily repeated, reproducible, and veriﬁable
during multidisciplinary tumor board meetings.
As aforementioned, the use of diﬀerent landmarks
has considerable implications, because distally located
rectal tumors are treated diﬀerently and carry worse
prognosis.4–8 Depending on tumor stage, low rectal
tumors may be treated by neoadjuvant radiotherapy
because of the small distance to the mesorectal
fascia.1 When a tumor is wrongly diagnosed as
middle–high at endoscopy instead of low by MRI, the
opportunity of transanal endoscopic microsurgery is
missed.2 Also, the surgical decision between a low
anterior resection and an abdominoperineal resection
is location dependent.2 Moreover, low rectal tumors
carry an increased risk of postoperative complications
and local tumor recurrence, resulting in worse sur-
vival.4–8 Although international clinical guidelines rec-
ommend the anal verge as a landmark, determination
of the anal verge or dentate line is subjective and
dependent on the experience of the endoscopist.
Consequently, surgeons favor the use of the
ARJ—the landmark used by radiologists—as this rep-
resents the distal border of perirectal fat in the mesor-
ectum, which is important to ensure a free resection
margin to the mesorectal fascia.
Our study has some strengths. To our knowledge
this is the ﬁrst study comparing colonoscopy and
MRI in determining rectal tumor height.16–18 Our
study was suﬃciently powered to detect diﬀerences
between MRI and endoscopy. Furthermore, all MRI
studies were reviewed for the study purpose and assess-
ment was performed systematically and standardized
for determining the ARJ and rectal tumor height.3,12
The main limitation of this study is the retrospective
design. Patient data were extracted from the database
alone. Potentially relevant information not included in
the database could have been missed. Also, the eﬀect of
Table 2. Tumor distribution in groups as measured by magnetic
resonance imaging (MRI) and endoscopy
Endoscopy
Low Middle High Total
MRI Low 85 39 6 130
Middle 5 41 25 71
High 0 1 9 10
Total 90 81 40 211
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intraobserver bias in the endoscopic measurements
could not be studied, e.g. potential diﬀerences in meas-
urement may depend on the experience of the
endoscopist.
In conclusion, this study showed that MRI and col-
onoscopy diﬀer considerably in determining rectal
tumor height. A signiﬁcant proportion of rectal
tumors are endoscopically classiﬁed as middle–high
but low by MRI. This may lead to a less-eﬀective treat-
ment strategy in some patients. There is no consensus
among endoscopists as to how to technically measure
rectal tumor height, and the interobserver variability
of endoscopically determined rectal tumor height is
unknown. Conversely, measurement of rectal tumor
height byMRI showed excellent inter- and intraobserver
agreement. As opposed to landmarks used by endosco-
pists and those recommended by clinical practice guide-
lines, the MRI-deﬁned ARJ is highly relevant for
surgeons for optimal treatment planning. In line with
radiological guidelines, we suggest using rectal tumor
height as measured by MRI for diagnostic purposes
and treatment allocation in patients with rectal cancer.
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